SLC5A2 and diabetes mellitus: Further, recent cardiovascular outcome trials (CVOTs) have shown improvement of CV and renal outcomes in patients with and even without T2DM by treatment with SGLT2 inhibitors, and the American Diabetes Association/the European Association of the Study for Diabetes (EASD) recommend SGLT2 inhibitors as the mainstay of treatment of T2DM [4].